| Basics |
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
|
| IPO Date: |
December 7, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$542.96M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.21 | 2.81%
|
| Avg Daily Range (30 D): |
$0.72 | 2.30%
|
| Avg Daily Range (90 D): |
$0.72 | 2.45%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.99M |
| Avg Daily Volume (30 D): |
.5M |
| Avg Daily Volume (90 D): |
.47M |
| Trade Size |
| Avg Trade Size (Sh.): |
226 |
| Avg Trade Size (Sh.) (30 D): |
51 |
| Avg Trade Size (Sh.) (90 D): |
57 |
| Institutional Trades |
| Total Inst.Trades: |
1,705 |
| Avg Inst. Trade: |
$1.38M |
| Avg Inst. Trade (30 D): |
$1.75M |
| Avg Inst. Trade (90 D): |
$1.65M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.55M |
| Avg Closing Trade (30 D): |
$1.95M |
| Avg Closing Trade (90 D): |
$1.98M |
| Avg Closing Volume: |
56.29K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$5.5
|
$3.33
|
$.64
|
|
Diluted EPS
|
$5.42
|
$3.28
|
$.63
|
|
Revenue
|
$ 267.92M
|
$ 101.69M
|
$ 53.33M
|
|
Gross Profit
|
$ 245.19M
|
$ 97.18M
|
$ 48.92M
|
|
Net Income / Loss
|
$ 97.82M
|
$ 59.61M
|
$ 11.45M
|
|
Operating Income / Loss
|
$ 104.59M
|
$ 61.1M
|
$ 12.77M
|
|
Cost of Revenue
|
$ 22.73M
|
$ 4.5M
|
$ 4.41M
|
|
Net Cash Flow
|
$ 17.41M
|
$ 7.68M
|
$ -10.96M
|
|
PE Ratio
|
5.61
|
|
|
| Splits |
|
Jun 27, 2024:
1:10
|
|
Jun 25, 2003:
1:9
|
|
|
|
